Investigational drug · Phase 2
SNP318
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Macular Edema, DME.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SNP318"
First trial start
2025
Nov 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SNP318", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema
- DME
Approved drugs for the same conditions: Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "SNP318" as an intervention, largest first.
SciNeuroIndustry
NCT05792163 · 76 participants · Start Mar 20, 2023 · Primary completion Nov 29, 2023
Drug: SNP318 (A); Placebo (B) · For: Neurodegenerative Diseases; Alzheimer's Disease
Sites: Adelaide, Australia
- A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME PatientsNot yet recruiting
SciNeuroIndustry
NCT07199777 · 60 participants (planned) · Start Nov 2025 · Primary completion Nov 2026
Drug: SNP318; Placebo · For: Diabetic Macular Edema; DME
Newest research
PubMed records naming it or its code names, newest first.
- Polymorphism analysis of CTLA-4 in childhood acute lymphoblastic leukemia.
Hui L, Lei Z, Peng Z, et al. · Pak J Pharm Sci 2014
Also in development for Diabetic Macular Edema
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- OCS-01Phase 32 trials
Oculis · Diabetic Macular Edema
- AVT29proposed aflibercept HD biosimilarPhase 31 trial
Alvotech Swiss AG · Diabetic Macular Edema
- Intravitreal RanibizumabPhase 31 trial
Roche (Genentech) · Diabetic Macular Edema
- BI 3812465Phase 21 trial
Boehringer Ingelheim · Diabetic Macular Edema
- CU06-1004Phase 21 trial
Curacle Co., Ltd. · DME, Diabetic Macular Edema, Diabetic Macular Edema (DME)
- OXU-001DEXAspheresPhase 21 trial
Oxular Limited · Diabetic Macular Edema
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.